NASDAQ:GALT - Galectin Therapeutics Inc. Common Stock Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.45 +0.58 (+14.99 %)
(As of 08/21/2018 03:56 AM ET)
Previous Close$3.87
Today's Range$3.91 - $4.47
52-Week Range$1.28 - $9.49
Volume747,200 shs
Average Volume724,743 shs
Market Capitalization$182.83 million
P/E Ratio-9.08
Dividend YieldN/A
Beta2.29
Galectin Therapeutics Inc. Common Stock logoGalectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.

Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GALT
CUSIPN/A
Phone678-620-3186

Debt

Debt-to-Equity RatioN/A
Current Ratio2.05
Quick Ratio2.05

Price-To-Earnings

Trailing P/E Ratio-9.08
Forward P/E Ratio-9.67
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.22) per share
Price / Book-20.23

Profitability

EPS (Most Recent Fiscal Year)($0.49)
Net Income$-16,230,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-244.78%

Miscellaneous

Employees7
Outstanding Shares40,910,000
Market Cap$182.83 million

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) Frequently Asked Questions

What is Galectin Therapeutics Inc. Common Stock's stock symbol?

Galectin Therapeutics Inc. Common Stock trades on the NASDAQ under the ticker symbol "GALT."

How were Galectin Therapeutics Inc. Common Stock's earnings last quarter?

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) released its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.02. View Galectin Therapeutics Inc. Common Stock's Earnings History.

When is Galectin Therapeutics Inc. Common Stock's next earnings date?

Galectin Therapeutics Inc. Common Stock is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Galectin Therapeutics Inc. Common Stock.

What price target have analysts set for GALT?

3 brokers have issued 1 year price objectives for Galectin Therapeutics Inc. Common Stock's stock. Their predictions range from $5.00 to $12.00. On average, they expect Galectin Therapeutics Inc. Common Stock's stock price to reach $8.3333 in the next year. This suggests a possible upside of 87.3% from the stock's current price. View Analyst Price Targets for Galectin Therapeutics Inc. Common Stock.

What is the consensus analysts' recommendation for Galectin Therapeutics Inc. Common Stock?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics Inc. Common Stock in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galectin Therapeutics Inc. Common Stock.

Who are some of Galectin Therapeutics Inc. Common Stock's key competitors?

Who are Galectin Therapeutics Inc. Common Stock's key executives?

Galectin Therapeutics Inc. Common Stock's management team includes the folowing people:
  • Dr. Harold H. Shlevin, Pres & CEO (Age 68)
  • Mr. Jack W. Callicutt, Chief Financial Officer (Age 51)
  • Robert Tritt, Gen. Counsel
  • Dr. Eliezer Zomer, Exec. VP of Manufacturing & Product Devel. (Age 71)
  • Mr. Steven Schubert, VP of Fin.

Has Galectin Therapeutics Inc. Common Stock been receiving favorable news coverage?

News stories about GALT stock have been trending somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Galectin Therapeutics Inc. Common Stock earned a media and rumor sentiment score of 0.09 on Accern's scale. They also assigned press coverage about the company an impact score of 47.21 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Galectin Therapeutics Inc. Common Stock.

Who are Galectin Therapeutics Inc. Common Stock's major shareholders?

Galectin Therapeutics Inc. Common Stock's stock is owned by a variety of of institutional and retail investors. Top institutional investors include D.A. Davidson & CO. (1.62%), BlackRock Inc. (1.45%), EAM Investors LLC (0.54%), EAM Global Investors LLC (0.40%), ING Groep NV (0.12%) and Belpointe Asset Management LLC (0.11%). Company insiders that own Galectin Therapeutics Inc. Common Stock stock include Fund LP 10X, Harold H Shlevin, Jack W Callicutt, James C Czirr, Joel Lewis, Kevin D Freeman, Marc Rubin, Peter G Traber and Theodore Daniel Zucconi. View Institutional Ownership Trends for Galectin Therapeutics Inc. Common Stock.

Which institutional investors are selling Galectin Therapeutics Inc. Common Stock stock?

GALT stock was sold by a variety of institutional investors in the last quarter, including EAM Investors LLC, D.A. Davidson & CO., EAM Global Investors LLC and Wedbush Securities Inc.. Company insiders that have sold Galectin Therapeutics Inc. Common Stock company stock in the last year include Fund LP 10X, Harold H Shlevin, Jack W Callicutt, James C Czirr, Peter G Traber and Theodore Daniel Zucconi. View Insider Buying and Selling for Galectin Therapeutics Inc. Common Stock.

Which institutional investors are buying Galectin Therapeutics Inc. Common Stock stock?

GALT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., ING Groep NV, Belpointe Asset Management LLC, Renaissance Technologies LLC, First Allied Advisory Services Inc. and Argent Trust Co. Company insiders that have bought Galectin Therapeutics Inc. Common Stock stock in the last two years include Joel Lewis, Kevin D Freeman, Marc Rubin and Theodore Daniel Zucconi. View Insider Buying and Selling for Galectin Therapeutics Inc. Common Stock.

How do I buy shares of Galectin Therapeutics Inc. Common Stock?

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galectin Therapeutics Inc. Common Stock's stock price today?

One share of GALT stock can currently be purchased for approximately $4.45.

How big of a company is Galectin Therapeutics Inc. Common Stock?

Galectin Therapeutics Inc. Common Stock has a market capitalization of $182.83 million. The company earns $-16,230,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Galectin Therapeutics Inc. Common Stock employs 7 workers across the globe.

How can I contact Galectin Therapeutics Inc. Common Stock?

Galectin Therapeutics Inc. Common Stock's mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]


MarketBeat Community Rating for Galectin Therapeutics Inc. Common Stock (NASDAQ GALT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  404
MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics Inc. Common Stock and other stocks. Vote "Outperform" if you believe GALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GALT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel